REGENXBIO Inc. (RGNX) CEO Ken Mills on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
REGENXBIO Reports Second Quarter 2021 Financial Results and Operational HighlightsPRNewsWire • 08/09/21
REGENXBIO to Host Conference Call on August 9 to Discuss Second Quarter 2021 Financial Results and Recent Operational HighlightsPRNewsWire • 08/02/21
Regenxbio's Hunter Syndrome Gene Therapy Shows Efficacy Signals, Cognitive Development Up To Two YearsBenzinga • 05/14/21
REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual MeetingPRNewsWire • 05/14/21
REGENXBIO Inc. (RGNX) CEO Ken Mills on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/06/21
REGENXBIO Reports First Quarter 2021 Financial Results and Operational HighlightsPRNewsWire • 05/05/21
REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational HighlightsPRNewsWire • 04/28/21
REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual MeetingPRNewsWire • 04/27/21
REGENXBIO To Present at the Chardan 5th Annual Genetic Medicines Manufacturing SummitPRNewsWire • 04/21/21
REGENXBIO Announces Dosing of First Patient in Cohort 3 of Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome)PRNewsWire • 04/14/21
REGENXBIO, Inc. (RGNX) CEO Ken Mills on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/02/21
REGENXBIO Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational HighlightsPRNewsWire • 03/01/21
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/17/21